Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in the 10th Annual Roth Technology Conference on November 17, 2021. Due to Covid-19, the meetings will occur virtually. Investors interested in meetings can contact Akoustis' investor relations. The company is ramping up production capacity at its New York facility to 500 million RF filters per year, driven by demand for its WiFi 6 and 5G products. Akoustis aims to address the growing RF filter market with its innovative XBAW™ technology.
Akoustis Technologies, Inc. (NASDAQ: AKTS) will participate in the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021. Meetings will be held virtually in light of COVID-19 precautions. Interested investors can schedule meetings via the Craig-Hallum representative or by contacting Akoustis' investor relations at ir@akoustis.com.
The company is expanding its production capacity at its New York facility to approximately 500 million filters annually by year-end 2021, driven by demand for 5G and Wi-Fi 6 technologies.
Akoustis Technologies (NASDAQ: AKTS) has engaged with a new mobile customer to develop its XBAW™ filters for challenging 4G/5G bands, marking its third customer engagement in the mobile sector. The customer, a leading RF component company targeting Asian OEMs, aims to expand its use of XBAW™ filters if initial projects meet specifications. Akoustis plans to deliver samples in H1 2022 and ramp production capacity to 500 million filters annually by year-end 2021. The company currently offers 15 products in its XBAW™ catalog, with new WiFi 6E solutions under development.
Akoustis Technologies reported a remarkable 290% year-over-year revenue growth, totaling $1.9 million for Q1FY22, aligning with previous guidance. The company anticipates a sequential revenue increase of nearly 100% for December 2021, with guidance between $3.5 million and $4.0 million. Akoustis is witnessing solid demand for its XBAW filters, particularly in 5G and WiFi 6E markets, with plans to increase production capacity to 500 million filters per year by year-end. Despite current headwinds, the company maintains a strong cash position of $75.7 million.
Akoustis Technologies (NASDAQ: AKTS) announced preliminary unaudited revenue of $1.9 million for Q1 FY22, close to its target of $2.0 million. The company expects to increase revenue to between $3.5-$4.0 million in the upcoming quarter, aided by new WiFi 6E and network infrastructure clients. Akoustis is expanding its production capacity to approximately 500 million filters annually at its New York facility by year-end 2021. The company continues to innovate in the RF filter market, with plans to introduce a total of 17 commercial XBAW filters.
Akoustis Technologies, Inc. (AKTS) announced a strategic acquisition of a 51% stake in RFM Integrated Device, Inc. (RFMi) for $6 million in cash and $2.5 million in stock, with an option to buy the remaining 49% for an additional $3.5 million in cash and $4 million in stock by June 2022. This acquisition enhances Akoustis' RF filter product portfolio, introduces new sales channels in various markets, and is expected to generate $500,000 to $1 million in revenue in the December quarter. The integration aims to leverage multi-chip modules for 4G/5G expansion and support increasing production capacities.
Akoustis Technologies, Inc. (NASDAQ: AKTS) is collaborating with a key Timing RF Component manufacturer to develop ultra-high frequency XBAW resonators for 5G wireless, networking, and automotive applications. Production is expected to ramp up by late 2022 or early 2023. The timing RF market presents significant growth opportunities for Akoustis, as it seeks to replace older technologies with its advanced devices. The company plans to increase its annual production capacity to approximately 500 million filters by the end of 2021, focusing on its expanding portfolio, including 15 commercial XBAW filters.
Akoustis Technologies has secured its third design win for its patented WiFi 6E XBAW filters, producing a 5.5 GHz/6.5 GHz tandem filter solution for a new MU-MIMO gateway product by a tier-1 OEM. The company anticipates a production ramp in early 2022, enhancing its role in the WiFi 6E market. With plans to boost annual production capacity at its New York facility to 500 million filters by year-end 2021, Akoustis aims to capitalize on the growing demand for RF filter technology.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in the 23rd Annual HC Wainwright Global Investment Conference on September 14, 2021. The meetings will be held virtually due to COVID-19 precautions. The company is focused on delivering high-volume production of its WiFi 6 tandem filters and expanding its 5G filter offerings. By the end of 2021, Akoustis plans to increase its annual production capacity to approximately 500 million filters. Currently, it has 15 commercial XBAW™ filters with plans to add more, targeting growth in the multi-billion-dollar RF filter market.
Akoustis Technologies, Inc. (NASDAQ: AKTS) is set to participate in the Piper Sandler Global Technology Conference on September 13, 2021. Due to COVID-19, the conference will be held virtually. Akoustis is ramping up production capacity at its New York facility to 500 million filters annually in response to increased demand for 5G and WiFi 6 technologies. The company currently offers 15 XBAWTM RF filters and plans to expand its catalog to 17 with the introduction of new WiFi 6E filters.
For investor inquiries, contact ir@akoustis.com.